CMA costs dispute goes to Supreme Court
Credit: Shutterstock/Fahroni
The UK's Supreme Court has permitted Flynn Pharma and Pfizer to appeal against a ruling that required the drug companies to pay the costs of their successful appeal against a decision by the UK's Competition and Markets Authority.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Subscribe now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10